Sjogren’s syndrome: evolving therapies

By Fox Robert I  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 2, 2003-02 ,pp. : 247-254

Informa Healthcare

Access to resources Recommend Favorite

Sjogren’s syndrome: models of pathogenesis and treatment targets

By Derk Chris T  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 11, 2005-11 ,pp. : 1587-1594

Informa Healthcare

Access to resources Recommend Favorite

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

By Bornstein Gadi   Quéva Christophe   Tabrizi Mohammad   Abbema Anne   Chavez Carlos   Wang Ping   Foord Orit   Ahluwalia Kiran   Laing Naomi   Raja Sandhya   Wen Shenghua   Green Larry   Yang Xiaodong   Webster Carl   Stewart Ross   Blakey David  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 561-574

Springer Publishing Company

Access to resources Recommend Favorite

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

By Castillo Jorge   Milani Cannon   Mendez-Allwood Daniel  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 491-500

Informa Healthcare

Access to resources Recommend Favorite

Zevalin TM: 90 Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin's Lymphoma

By  

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 341-349

Bentham Science Publishers

Access to resources Recommend Favorite